Trends in Targeted Therapy Usage in Inflammatory Bowel Disease : TRENDY Study of ENEIDA

C. Gómez-Labrador, Elena Ricart, Marisa Iborra, E. Iglesias, M.D. Martín-Arranz, L. de Castro, R. De Francisco, F.J. García-Alonso, A. Sanahuja, C.J. Gargallo-Puyuelo, F. Mesonero, M.J. Casanova, Míriam Mañosa i Ciria, Montserrat Rivero, M. Calvo, Mónica Sierra Ausín, C. González-Muñoza, Xavier Calvet Calvo, Hospital Universitario Miguel Servet, Jordi GuardiolaL. Arias García, Lucía Márquez-Mosquera, Ana Gutiérrez Casbas, Yamile Zabana, Mercè Navarro-Llavat, R. Lorente Poyatos, M. Piqueras, L. Torrealba, F. Bermejo, Á. Ponferrada-Díaz, J.L. Pérez-Calle, Manuel Barreiro de-Acosta, C. Tejido, José Luis Cabriada, I. Marín-Jiménez, Ó. Roncero, Y. Ber, L. Fernández-Salazar, B. Camps Aler, Alfredo J Lucendo, J. Llaó, L. Bujanda, C. Muñoz Villafranca, Eugeni Domènech, María Chaparro, Javier P. Gisbert

Producción científica: Contribución a una revistaArtículoInvestigaciónrevisión exhaustiva

Resumen

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
Idioma originalInglés
Número de artículo629
PublicaciónPharmaceutics
Volumen16
N.º5
DOI
EstadoPublicada - may 2024

Huella

Profundice en los temas de investigación de 'Trends in Targeted Therapy Usage in Inflammatory Bowel Disease : TRENDY Study of ENEIDA'. En conjunto forman una huella única.

Citar esto